ARYA Sciences Acquisition Corp IV is a
special purpose acquisition company formed for the purpose of entering into a combination with one or more
businesses or entities. While the Company may pursue an initial business combination target in any business or industry, it intends to focus on the healthcare industry in the United States and other developed countries. The Company intends to focus on target businesses with valuations of $300 to $500 million or more and that have the potential to be $1 billion or more market capitalization companies.
Company profile
Ticker
ARYD
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aja Holdco, Inc. ...
ARYD stock data
Latest filings (excl ownership)
425
Business combination disclosure
23 Apr 24
8-K
ADAGIO MEDICAL Investor Presentation | April 2024 1
23 Apr 24
425
Business combination disclosure
2 Apr 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
2 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
425
Business combination disclosure
28 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Mar 24
425
Business combination disclosure
25 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
28 Feb 24
425
Business combination disclosure
28 Feb 24
Latest ownership filings
SC 13G
Shaolin Capital Management LLC
14 Feb 24
SC 13G/A
GLAZER CAPITAL, LLC
14 Feb 24
SC 13G
TENOR CAPITAL MANAGEMENT Co., L.P.
14 Feb 24
SC 13G
MIZUHO FINANCIAL GROUP INC
13 Feb 24
SC 13G
PERISCOPE CAPITAL INC.
9 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
SC 13G/A
Farallon Capital Partners, L.P.
18 Jan 24
SC 13G/A
GLAZER CAPITAL, LLC
10 Mar 23
SC 13G
Radcliffe Capital Management, L.P.
8 Mar 23
SC 13G/A
TIG Advisors, LLC
14 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 13.81 k | 13.81 k | 13.81 k | 13.81 k | 13.81 k | 13.81 k |
Cash burn (monthly) | 1.41 k | 777.00 | 319.89 k | 189.85 k | 9.74 k | 61.19 k |
Cash used (since last report) | 9.66 k | 5.33 k | 2.19 mm | 1.30 mm | 66.82 k | 419.76 k |
Cash remaining | 4.15 k | 8.48 k | -2.18 mm | -1.29 mm | -53.02 k | -405.95 k |
Runway (months of cash) | 2.9 | 10.9 | -6.8 | -6.8 | -5.4 | -6.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 6 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 26.16 bn |
Total shares | 45.60 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sciences Holdings IV ARYA | 41.47 mm | $0.00 |
Farallon Capital Partners | 751.00 k | $0.00 |
Glazer Capital | 497.45 k | $5.38 mm |
Westchester Capital Management | 419.08 k | $4.55 bn |
Shaolin Capital Management | 413.05 k | $4.47 mm |
TENOR CAPITAL MANAGEMENT | 300.00 k | $3.25 bn |
Periscope Capital | 300.00 k | $3.25 bn |
Farallon Capital Management | 200.00 k | $2.17 bn |
Cowen And | 192.56 k | $2.08 bn |
Meteora Capital | 180.37 k | $1.95 bn |